ALLUVI: A DEEP EXPLORATION INTO THE MEDICATION'S PROMISE

Alluvi, formerly LY3414901, represents a significant advancement in obesity management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist exhibits remarkable impact in early clinical data, with considerable reduction in we